Divergent pathways for melanoma: what is the role of genetics?

R Ghiasvand^{1

2}

Affiliations

¹ Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
² Department of Research, Cancer Registry of Norway, PB 5313 Majorstuen, Oslo, 0304, Norway.

Comment

R Ghiasvand. Br J Dermatol. 2021 Jun.

. 2021 Jun;184(6):995-996.

doi: 10.1111/bjd.19887. Epub 2021 Mar 25.

R Ghiasvand^{1

2}

¹ Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
² Department of Research, Cancer Registry of Norway, PB 5313 Majorstuen, Oslo, 0304, Norway.

No abstract available

Comment on

Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
Laskar R, Ferreiro-Iglesias A, Bishop DT, Iles MM, Kanetsky PA, Armstrong BK, Law MH, Goldstein AM, Aitken JF, Giles GG; Australian Melanoma Family Study Investigators; Leeds Case-Control Study Investigators; Robbins HA, Cust AE. Laskar R, et al. Br J Dermatol. 2021 Jun;184(6):1085-1093. doi: 10.1111/bjd.19705. Epub 2021 Feb 18. Br J Dermatol. 2021. PMID: 33270213 Free PMC article.

1. Green A. A theory of site distribution of melanomas: Queensland, Australia. Cancer Causes Control 1992; 3:513-16.
1. Whiteman DC, Watt P, Purdie DM et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806-12.
1. Laskar R, Ferreiro-Iglesias A, Bishop D et al. Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity. Br J Dermatol 2021; https://doi.org/10.1111/bjd.19705.
1. Cust AE, Drummond M, Kanetsky PA et al. Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies. J Invest Dermatol 2018; 138:2617-24.
1. Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene 2017; 36:5771-92.